Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT) Meeting Abstract
| Authors: | Kewalramani, T.; Zelenetz, A.; Bertino, J.; Donnelly, G.; Hedrick, E.; Noy, A.; O'connor, O.; Portlock, C.; Straus, D.; Yahalom, J.; Gencarelli, A.; Remy, D.; Qin, J.; Nimer, S.; Moskowitz, C. |
| Abstract Title: | Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT) |
| Meeting Title: | 43rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 98 |
| Issue: | 11 Pt. 1 |
| Meeting Dates: | 2001 Dec 7-11 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2001-11-16 |
| Start Page: | 346a |
| Language: | English |
| ACCESSION: | WOS:000172134101463 |
| PROVIDER: | wos |
| PUBMED: | 11727739 |
| Notes: | Meeting Abstract:1459 -- Source: Wos |
